TOKYO -- U.S. proxy advisory firm Institutional Shareholder Services (ISS) is recommending shareholders vote against the ...

Takeda Pharmaceutical Company Limited (NYSE:TAK)’s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized ...

The European Commission (EC) has approved Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) plus the ...

Takeda (NYSE:TAK) (4502.T) said on Monday that the European Commission approved Pfizer (NYSE:PFE) and the company's ...

This is the web version of STAT’s special newslette r from the annual meeting of the American Society of Oncology. For more ...

Osaka: Takeda has received approval from the European Commission (EC) for ADCETRIS (brentuximab vedotin) in combination with ...

The drug has been approved in combination with the chemotherapy regimen etoposide, cyclophosphamide, doxorubicin, dacarbazine ...

The first half of this year has been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...

"I am extremely proud that Takeda has been recognized as one of the top ten employers in the world for 2024. This confirms ...

We are pleased to partner with Takeda as we continue to advance rusfertide to potentially transform the standard of care in PV patients around the world.” “These promising pivotal data ...